Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) an emerging specialty pharmaceutical company, announced that additional safety data are being highlighted from its Phase 3 trial of EXPAREL™ (bupivacaine extended-release liposome injection) in bunionectomy. The data showed comparable safety in wound healing and significantly improved efficacy in pain reduction compared to placebo. These results are being highlighted in a poster presentation at the 2011 American Academy of Orthopaedic Surgeons Annual Meeting in San Diego, Calif. (Read More http://crweselect.com/20893/stock-alerts/pcrx-orfgpk-dtlk-avotpk-mrge-cr... )
PCRX, ORFG.PK, DTLK, AVOT.PK, MRGE, - CRWESelect.com Stock Report! Pacira Pharmaceuticals, Orofino Gold Corp., Datalink Corp.
- , precious metals, molybdenum, merge, ORFG, ORFG.PK, Orofino Gold, pink:ORFG, precious minerals, gold properties, NASDAQ:MRGE, mineral exploration, American Video Teleconferencing, AVOT.PK, Mekinac, Lajuene, Quebec, PINK:AVOT, metal projects, quebec department of mines, AVOT, Province of Quebec, Ary Pernett, Bogota, chalcopyrite, Colombia, Culo Alzado, galena, La Azul, Medellin, quartz viens, San Carlos, Senderos de Oro, sphalerite, pyrite, molybdenum property, China based Gold, Silver Exploration, Salvador Rivero, Datalink, Nasdaq:DTLK, NASDAQ:PCRX, Pacira